Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Non-Deal Roadshow (August 2020)
80 slides from Coloplast A/s Class B's roadshow presentation, August 2020
Slide 1: Making it easier to be yourself
Making it easier to be yourself Clothes are a part of my identity, so I worried about what I could wear after my operation. Today, I still dress the way I want. Stina Leading intimate healthcare Roadshow presentation 9M 2019/20 Making life easier Ostomy Care, Continence Care, Wound & Skin Care and I
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Coloplast strengthens Executive Management
Coloplast strengthens Executive Management • Coloplast Executive Leadership Team is expanded from four to six people in order to deliver on upcoming 2025 strategy centred around Innovation and Growth, which will be presented at the Capital Markets Day on September 29th Kristian Villumsen New role EV
Slide 4: Coloplast organization as of October 1, 2020
Coloplast organization as of October 1, 2020 = Executive Leadership Team Kristian Villumsen President & CEO Nicolai Buhl Anders Lonning- Camilla G. Møhl Steve Blum Paul Marcun Allan Rasmussen Andersen Skovgaard SVP People & SVP Interventional EVP Growth EVP Operations EVP Innovation CFO & EVP Cultur
Slide 5: An update on how Coloplast is navigating the COVID-19 pandemic
An update on how Coloplast is navigating the COVID-19 pandemic • Three key priorities: keeping our people safe, continuing to serve our customers and maintaining business operations • Global guidelines, safety measures and contingency plans implemented • Support consumers with dependable delivery of
Slide 6: Q3 negatively impacted by decline in elective procedures in Interventional Urology
Q3 negatively impacted by decline in elective procedures in Interventional Urology and reversal of stock building in EU Q3 Highlights Revenue growth +5% • Negative organic growth of -2% and -4% reported decline in DKK Reported revenue (DKKm) +5% • Chronic Care delivered a stable underlying growth in
Slide 7: Q3 significantly impacted across all business areas and regions by COVID-19
Q3 significantly impacted across all business areas and regions by COVID-19 Revenue by business area Revenue by geography Business Reported revenue Q3 Organic growth Organic growth Geographic Reported revenue Q3 Organic growth Organic growth area DKKm Q3 YTD area DKKm Q3 YTD Ostomy Care 1,870 4% 8%
Slide 8: Ostomy Care grew 4% organically in Q3
Ostomy Care grew 4% organically in Q3, adversely impacted by reversal of previous stock building in Europe in Q2 Ostomy Care performance Comments • 9M organic growth of 8% (reported growth 7%). Q3 organic growth of 10 10 4% (reported growth 2%) 9 9 9 • In Q3, growth was driven by the US and China bu
Slide 9: Continence Care grew 4% organically in Q3
Continence Care grew 4% organically in Q3, adversely impacted by reversal of previous stock building in Q2 Continence Care performance Comments 12 • 9M organic growth of 7% (reported growth 7%). Q3 organic growth of 4% (reported growth 2%) • In Q3, growth was driven by the US 9 • Sales growth in Q3
Slide 10: Interventional Urology declined 40% organically in Q3
Interventional Urology declined 40% organically in Q3, due to COVID-19 and a decline in elective procedures Interventional Urology performance Comments • 9M negative organic growth of -10% (-8% reported growth). Q3 14 14 negative organic growth of -40% (-39% reported growth) 11 12 10 9 • Growth in Q
Slide 11: Wound delivered negative -7% organic growth in Q3
Wound delivered negative -7% organic growth in Q3 due to decline in hospital procedures in China and France Wound & Skin Care performance Comments • 9M organic growth of 2% in Wound & Skin Care (2% reported 11 growth). Q3 negative organic growth of -6% in Wound & Skin Care 9 10 (-7% reported growth)
Slide 12: Q3 2019/20 reported revenue declined -4%
Q3 2019/20 reported revenue declined -4% due to Interventional Urology and reversal of stocking as well as FX Comments Revenue development • Q3 2019/20 reported revenue decline by DKK 180m or (DKKm) -4% compared to Q3 2018/19 4,599 -97 • The decline was due to an underlying decline in sales of DKK 9
Slide 13: EBIT declined -5% in Q3
EBIT declined -5% in Q3 due to lower revenues as a result of the COVID-19 outbreak; prudent cost control exercised Comments EBIT margin development (%) • Q3 gross margin of 67% in DKK compared to 68% last year 1.3 • Positive impact from GOP4 and the closure of the Thisted factory in June 2019 • Nega
Slide 14: FCF driven by positive underlying development in earnings
FCF driven by positive underlying development in earnings FCF development Comments • Free cash flow in 9M 2019/20 was DKK 2,436m, up 10% compared to DKK 2,215m in 9M 2018/19 98 99 98 • Adjusted for the positive impact of DKK 144m related to the 93 96 92 reclassification of lease payments following t
Slide 15: Financial guidance for FY 2019/20 – guidance range narrowed
Financial guidance for FY 2019/20 – guidance range narrowed Guidance 2019/20 Guidance 2019/20 (DKK)* Key assumptions • The situation in Interventional Urology gradually normalises in Q4 • Majority of 150m stock building from Q2 reversed in Q3 – expected to ~4% fully reverse in Q4 3-4% Sales growth f
Slide 16: Capital Markets Day 2020
Capital Markets Day 2020 14.00 pm - 17.00 pm CEST 13.00 pm - 16.00 pm BST 08.00 am - 11.00 am EDT Join us virtually or at our venue in Humlebaek, north of Copenhagen. This event is intended to give institutional investors and equity analysts an introduction to the new long-term strategy. More inform
Slide 17: Leading intimate healthcare: Introduction to Coloplast
Leading intimate healthcare Introduction to Coloplast
Slide 18: Coloplast has four business areas all with global sales presence
Coloplast has four business areas all with global sales presence Group revenue 2018/19 by segment Group revenue 2018/19 by geography X = Coloplast’s global market position Emerging markets 17% Ostomy Care Continence 40% Care 36% #1 DKK DKK 17.9bn #1 Other 17.9bn European developed markets markets 59
Slide 19: Coloplast specializes in intimate healthcare needs
Coloplast specializes in intimate healthcare needs Who are our typical users How do we help them? People who have had their intestine redirected to an SenSura® Mio opening in the abdominal wall Ostomy bag Ostomy Care People in need of bladder or bowel management SpeediCath® Continence Flexible male
Slide 20: The Chronic Care model secures a predictable revenue stream
The Chronic Care model secures a predictable revenue stream and stable revenue growth The chronic care user flow Chronic Care condition New user Installed base of users Stable flow of loyal users Solid reimbursement Coloplast group revenues Revenue (DKKbn) Organic growth (%) 10 10 9 8 8 8 8 7 7 7 7
Slide 21: Intimate healthcare is characterized by stable industry trends
Intimate healthcare is characterized by stable industry trends Drivers Limiters Earlier detection and Growing elderly Surgical and cure, eventually 1 Demographics population increases 1 medical trends reduces addressable customer base for market for Coloplast Coloplast products treatment products Ex
Slide 22: Strong market positions in Europe and commercial potential outside Europe
Coloplast has strong market positions in Europe and great commercial potential outside Europe Europe Developed Emerging Ostomy Continence Urology Wound Care Addressable market 18-19n 13-14bn 12-13bn 22-24bn 4-5% 5-6% 3-5% 2-4% Size in DKK Growth in %1 Coloplast 40 - 50% 45 - 55% 20 - 25% 5 - 10% reg
Slide 23: Building the consumer healthcare company of the future
We are building what we believe is the consumer healthcare company of the future Superior Clinical Consumer Payer products & preference preference preference innovation Care, DtC & Direct Data and digital tools Page 23
Slide 24: LEAD20 strategy focused on revenue and earnings growth
Coloplast’s LEAD20 strategy was focused on revenue and earnings growth across 4 major themes 1 Superior products & innovation 2 Unique user focused market approach 3 Unparalleled efficiency 4 Strong leadership development Page 24
Slide 25: Long-term guidance for the LEAD20 strategy period
Long-term guidance for the LEAD20 strategy period aimed at accelerating growth and long-term value creation Revenue growth EBIT margin annual organic constant currencies 7–9% >30% Page 25
Slide 26: Investment strategy has a balanced approach
To fuel growth & sustain long-term competitive advantage, our investment strategy has a balanced approach Up to 2% of sales invested annually across… …functions …geographies …and time horizons 15/16-18/19 15/16-18/19 Short term: Sales force, marketing and infrastructure • Optimize and expand our com
Slide 27: Global Coloplast Care and DtC presence
Our global Coloplast Care and DtC presence enables us to support users across countries and business areas Over 1M consumers in our database Over 1M conversations with users across the globe Over 30 countries with a consumer setup New Bowel Care program implemented in 2018 Coloplast Care & DTC offer
Slide 28: Ambitious Clinical Performance Program
We have initiated a very ambitious Clinical Performance Program to tackle the biggest issues users face What really matters to people using catheters? What really matters to people living with a stoma? 45 %* of users describe UTIs are their 93 % worry about leakage2 greatest challenge in life1 * Peo
Slide 29: Through digitalization of new products, we take the next step
Through digitalization of new products, we will take the next step towards our mission of making life easier for our users Digitalization in product development as first important milestone Payers Digitalization • We have a mission of making life easier Direct for people with intimate healthcare Glo
Slide 30: Burden of illness study in Germany shows significant payer costs
Example: Results from a burden of illness study in Germany show significant payer costs linked to ostomates Data Total cost per year Total cost split ostomates(1) EUR Inpatient Stoma products German claims database Colostomy, ileostomy and nursing 2.5m beneficiaries x3 and urostomy Outpatient Other
Slide 31: Global Operation Plan 4 supports LEAD20
Global Operation Plan 4 aims to support LEAD20 through continued unparalleled efficiency and financial discipline Global Operations Plan 4 1. Reduction of manufacturing in Denmark EBIT margin contribution, bps Manufacturing FTE’s in Denmark, Ultimo FY GOP 3 GOP 4 700 600 50 500 375 21% 225 100 Salar
Slide 32: Profitability supported by scalability and efficiency gains
Profitability supported by scalability and efficiency gains enabling additional investments within distribution and R&D Gross margin development, in % of revenue Cost item Development, in % of revenue + 0.5%-points 28.5 28.1 28.1 28.7 29.0 28-30 Distribution 68.5 68.3 68.1 67.3 67.7 - 0.1%-points 4.
Slide 33: Global Business Support and IT landscape
A global Business Support and IT landscape enables Coloplast to scale faster and more efficiently Global Business Services Global business services handle the majority of all global support % of group processes 100% ~90% 100% IT infrastructure Finance/ Master Data Global Business & support accountin
Slide 34: We will continue to deliver strong free cash flows
We will continue to deliver strong and attractive free cash flows … Taxation Net working capital CAPEX(2) Reported tax rate, % Net working capital in % revenue Depreciation in % of revenue CAPEX DKKm CAPEX in % of revenue 4.4 28 24 24 25 24 3.8 4-5% 23 24 23 23 23 23 23 2.5 2.8 649 685 669 690 617 1
Slide 35: Attractive cash returns despite large investments
…and continue to provide attractive cash returns despite large investments in commercial and expansion activities Coloplast cash distribution to investors Comments • Coloplast returns excess liquidity to Dividends paid out in the year (mDKK) (1) Share buy-back (DKKm) Pay-out ratio (%) (2) shareholde
Slide 36: Key highlights from 2018/19 Corporate Responsibility initiatives
Key highlights from 2018/19 Corporate Responsibility initiatives Empowering People Acting respectfully Minimising footprint Our Access to Healthcare programme has New target to increase share of diverse teams Achieved 100% electricity from supported 62 projects since 2007. (gender, generation, natio
Slide 37: Coloplast can continue to deliver stable shareholder returns
In sum, we believe Coloplast can continue to deliver stable shareholder returns through ... 31% Comments • Long term stable market trends in our Chronic Care business • Strong Coloplast Care retention program and innovative DtC 10% activities 5% 9% • Increased focus on growing the business outside E
Slide 38: Appendices
Leading intimate healthcare Appendices
Slide 39: The Coloplast share (COLO-B.CO)
The Coloplast share (COLO-B.CO) Share Capital Ownership Coloplast share listed on Nasdaq Copenhagen since 1983 ~205 billion DKK (~33 billion USD) market cap @ ~1,041 DKK 11% per share (incl. A shares) 4% 2% Two share classes: 46% • 18m A shares carry 10 votes (family) • 198m B shares carry 1 vote (f
Slide 40: Capital structure
Capital structure Comments Net interest bearing debt • Overall policy is that excess liquidity is returned to shareholders through a combination of dividends and share buy- 0.1x 0.1x 0.1x -0.3x -0.2x backs • Interest bearing debt will be raised in connection with a major acquisition or other special
Slide 41: Year to date revenue and growth by segment
Year to date revenue and growth by segment 9M 19/20 revenue by business area 9M 19/20 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share of organic area DKKm growth area DKKm growth Ostomy Care 5,697 8% 63% European 8,168 3
Slide 42: 9M 2019/20 reported revenue grew 5%
9M 2019/20 reported revenue grew 5% driven by organic growth of 5% Comments Revenue development • 9M 2019/20 reported revenue increased by DKK 633m (DKKm) or 5% compared to 9M 2018/19 635 13,954 • The majority of growth was driven by organic growth -2 contributing DKK 635m or 5% to reported revenue
Slide 43: EBIT grew 7% in 9M 2019/20
EBIT grew 7% in 9M 2019/20 reflecting strong cost control during COVID-19 outbreak as well as sustained investments Comments EBIT margin development (%) • Gross margin of 68% in DKK compared to 67% last year • Positive impact driven by GOP4 and the closure of the Thisted factory 0.1 -0.1 in June 201
Slide 44: Key Value Ratios
Key Value Ratios Profitability drivers Free Cash Flow drivers 31.9 32.7 32.3 36.6 36.3 36.0 31.7 32.3 34.7 34.6 28.1 28.7 29.0 28.1 28.6 25.2 23.8 23.4 23.6 24.1 3.8 4.0 4.0 4.2 4.1 4.9 4.4 4.4 4.1 3.8 3.5 3.7 3.9 3.9 3.8 15/16 16/17 17/18 18/19 YTD 19/20 15/16 16/17 17/18 18/19 YTD 19/20 Admin-to-S
Slide 45: Coloplast revenue development by business area
Coloplast revenue development by business area Ostomy Care Interventional Urology 13 9 7,166 6,643 10 10 10 5,935 6,291 8 5,697 8 6 9 9 10 10 8 6 9 7 7 7 1,497 1,641 1,740 1,970 1,355 7 67 5 6 -8 -10 15/16 16/17 17/18 18/19 YTD 19/20 15/16 16/17 17/18 18/19 YTD 19/20 Continence Care Wound & Skin Car
Slide 46: Revenue development by geography and total
Coloplast revenue development by geography and total Europe Other Developed Markets 9,941 10,573 9,213 9,394 15 16 8,168 8 11 8 11 7 6 5 6 6 3,642 3,791 4,380 3,177 3,434 3 4 2 5 6 6 4 5 15/16 16/17 17/18 18/19 YTD 19/20 15/16 16/17(1) 17/18 18/19 YTD 19/20 Emerging Markets Coloplast group 17,939 16
Slide 47: Segment operating profit
Segment operating profit (Excludes shared/non-allocated costs) Chronic Care Interventional Urology Wound & Skin Care Ostomy and Continence Care 60 38 40 40 41 57 59 59 37 39 39 55 34 35 2,083 2,047 2,168 2,092 1,901 194 197 170 179 235 250 248 25 225 230 79 Q3 18/19 Q4 18/19 Q1 19/20 Q2 19/20 Q3 19/
Slide 48: Exchange rate exposure FY 2019/20 and hedging policy
Exchange rate exposure FY 2019/20 and hedging policy Revenue FX exposure 2019/20(1) 12 months exposure from 10% initial exchange rate drop(1) Other 15% -390 USD -170 EUR CNY, JPY, AUD, BRL & ARS 12% 39% -270 GBP -170 HUF 0 14% 110 GBP 20% Revenue (DKKm) EBIT (DKKm) USD Foreign exchange rate guidance
Slide 49: Mesh litigation timeline
Mesh litigation timeline Jan. 31, 2019: Verdict vs Ethicon PA State Court: USD 41M Jan. 21, 2020: Dec. 14, 2017: Verdict for Ethicon April 28, 2017: (DKK 354.3M) Sept. 9, 2014: Verdict vs Ethicon FL Federal Court: Verdict vs Ethicon NJ State Court: Verdict vs BSC Dec. 24, 2015: PA State Court: USD 1
Slide 50: US Mesh litigation – overview of financial impact
US Mesh litigation – Overview of current financial impact P&L Balance Cash flow Assets Actual/Expected cash flow, DKKbn 13/14 14/15 15/16 16/17 17/18 18/19 19/20 Restricted cash, DKKbn 0.5 0.5 EBIT (before special items) 4,147 4,535 4,846 5,024 5,091 5,556 3,014 Special items -1,000 -3,000 - 750 0 0
Slide 51: Health reform landscape
Health reform landscape Europe Rest of World • France: Reimbursement pressure on OC, CC and WC • U.S.: Healthcare reform implementation ongoing • Greece: Reimbursement pressure on all BAs • Argentina: Macroeconomic challenges • Germany: Reimbursement pressure on OC and CC • Brazil: Macroeconomic and
Slide 52: CARE helps increase retention and product compliance
CARE helps us increase retention and improve product compliance for in excess of 500,000 enrolled consumers We co-develop CARE content with CARE is a personal and “high- Global program with shared local clinicians touch” program infrastructure Advisors available on phone Clinically validated content
Slide 53: DtC marketing program reaches into the community
With our DtC marketing program we reach into the community We operate in numerous channels to expose our service …and with the reach we get several benefits and product offering… Expose innovative products Ensure product accessibility Ensure successful experience Page 53
Slide 54: Generic model for distribution and reimbursement
The generic model for distribution and reimbursement of our products Prescription & Insurance Product Payer Reimbursement price Distribution Prescription & Insurance Consumer $ Product DtC Marketing • Campaigns • Community • Relationships • Information Coloplast Page 54
Slide 55: Interventional Urology remains core to the Coloplast mission
Interventional Urology remains core to the Coloplast mission and value creation agenda Interventional Urology at a Glance ~15% market share in global market of DKK 13-14bn market FY 18/19 growing 3-5% annually 11% Coloplast position ENDOUROLOGY MEN’S HEALTH WOMEN’S HEALTH SPECIALTY INTERVENTIONS of
Slide 56: Interventional Urology is a DKK 12-13bn market
Interventional Urology is a DKK 12-13bn market growing 3-5% annually Business Area Market Dynamics Market Size (DKKbn) Market growth1 ~5 • Portfolio breadth increasingly valued Endourology ~5% • Single-use visualization significant opportunity 5 ~3 • Penile implant market responding to patient aware
Slide 57: Select products
Coloplast Interventional Urology is split into four business areas MEN’S WOMEN’S SPECIALTY ENDOUROLOGY HEALTH HEALTH INTERVENTIONS • Erectile Dysfunction • Stress Urinary Incontinence • Stone Management • Bladder Drainage • Male Incontinence (SUI) • Transurethral • Benign prostatic hyperplasia • Tes
Slide 58: Interventional Urology competitive overview
Interventional Urology competitive overview Market presence Company Men’s Health Women’s Health Endourology Specialty Interventions ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓/ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Page 58
Slide 59: The global AWC market remains large and growing
The global AWC market remains large and growing The Advanced Wound Care market remains a significant Silicone Foams and Gelling Fibers are the two biggest value pool and continues to grow across all regions categories and main growth contributors Market size in DKKbn RoW Silicone Foams Silicone Foam
Slide 60: In Wound Care we are progressing with our current strategy
In Wound Care we are progressing with our current strategy 1 Shape the standard Endorsements Publications Build a strong product 2 PIP portfolio 3 Accelerate in EU Ramp-up Strengthen position 4 in the US New structure New management New investment plan Secure leading position 5 in China Revised targ
Slide 61: US Ostomy Care: gaining share in acute, focus on home health
In US Ostomy Care, we continue to gain share in acute and have increased our focus on the home health channel US Ostomy patient pathway Continuing to gain share in the acute channel Patients +7 pts. Hospital 3-5 days 15/16 16/17 17/18 Recent acute contract wins PAC / HHA(1) ~75% of hospital >60 days
Slide 62: Introducing Ostomy Care
Introducing Ostomy Care Disease areas Key products Distribution of • Colorectal cancer (est. 45%) revenues* • Bladder cancer (est. 10%) • Diverticulitis (est. 15%) Urostomy • Inflammatory bowel disease (est. 10%) Ileostomy • Other (est. 20%) Colostomy Customer groups • Nurses, mainly stoma care nurs
Slide 63: Introducing Ostomy Care Supporting Products
Introducing Ostomy Care Supporting Products Market fundamentals Key products Brava® is a range of ostomy supporting products • Market size of DKK 2-3bn designed to reduce leakage or care for skin, to make • Market growth of 6-8% • Market share 30-35% Brava® Protective Seal our end-users feel secure.
Slide 64: Introducing Continence Care
Introducing Continence Care Disease areas Key products Distribution of • Spinal Cord Injured, SCI revenues • Spina Bifida, SB • Multiple Sclerosis, MS Intermittent catheters • Benign prostatic hyperplasia, BPH & prostatectomy patients Urine bags • Elderly Male ext. catheters Bowel management CC Othe
Slide 65: Introducing Bowel Management
Introducing Bowel Management Disease areas Market dynamics Faecal incontinence + Growing awareness (management products only) + Huge underpenetrated and Customer groups unserved population • Spinal Cord Injured, SCI + New devices addressing the many • Spina Bifida, SB unmet needs • Multiple Sclerosi
Slide 66: Introducing Interventional Urology
Introducing Interventional Urology Treatment (surgical) of urological disorders Disease areas Key products Distribution of revenues • Urinary incontinence • Pelvic organ prolapse Men’s health • Erectile dysfunction Women’s health • Enlarged prostate • Kidney and urinary stones Single use devices Cus
Slide 67: Introducing Wound Care
Introducing Wound Care Disease areas Key products Distribution of revenues Chronic wounds (WSC) • Leg ulcers Biatain® range • Diabetic foot ulcers Comfeel® range • Pressure ulcers Skin Care Wound Care other Customer groups Contract manufacturing & call points Hospitals Biatain® Silicone, incl. Sizes
Slide 68: Introducing Skin Care
Introducing Skin Care Disease areas Key products Product mix • Moisture associated skin damage Protectants & Antifungals • Incontinence Cleansing/Bathing • Skin folds & obesity Moisturizers • Prevention of skin impairments Textile SC Other Customer groups & call points Sween® EasiCleanse Bath® Hospi
Slide 69: Product market for US Skin Care
Product market for US Skin Care Market drivers/limiters US Skin Care at a glance + Aging and obese population • US market size estimated at DKK + CMS Value Based Purchasing 4-5bn with 2-4% growth1 + Increased focus on prevention + Increased importance of utilization • Market share: 10-15% management
Slide 70: The Coloplast organisation
The Coloplast organisation Coloplast Group Chronic Care Strategic Business Units Chronic Care Strategic Business Units Ostomy Care Continence Care Wound & Skin Care Interventional Urology R&D Marketing Sales R&D Marketing Marketing Operations Sales Regions Global Operations Global Business Support F
Slide 71: Coloplast Executive Leadership Team
Coloplast Executive Leadership Team Kristian Villumsen President, CEO • Born 1970 • With Coloplast since 2008 Nicolai Buhl Andersen Anders Lonning-Skovgaard Paul Marcun Camilla G. Møhl Allan Rasmussen EVP, Innovation EVP, CFO EVP, Growth SVP, People & Culture EVP, Operations • Born 1969 • Born 1972
Slide 72: Income statement
Income statement DKKm Q3 2018/19 Q3 2019/20 Change 9M 2018/19 9M 2019/20 Change Revenue 4,599 4419 -4% 13,321 13,954 5% Gross profit 3,123 2,970 -5% 8,983 9,452 5% SG&A costs -1513 -1,426 6% -4,A23 4,563 3% R&D costs -175 -182 4% -527 -533 1% Other operating income/expenses 3 6 100% 44 26 -41% Opera
Slide 73: Balance sheet
Balance sheet DKKm 30 Jun 2019 30 Jun 2020 Change Balance, total 12,551 13,315 6% Assets Non-current assets 6,136 6,825 11% Current assets 6,415 6,490 1% of which: Inventories 1,914 2,116 11% Trade receivables 3,227 2,997 -7% Amounts held in escrow 73 12 -84% Marketable securities, cash, and cash eq
Slide 74: Cash flow
Cash flow 1) Net CAPEX including divestment of PPE and excluding finance leases Page 74
Slide 75: Manufacturing setup
Manufacturing setup Production by country (Volume)¹ 5% Hungary 11% 2% Mørdrup China 1% Minneapolis Tatabánya Sarlat Nyirbátor US/France Mankato Denmark Zhuhai Costa Rica Costa Rica 81% COGS by cost type² 9% Salary - Direct 21% 12% Salary - Indirect Materials (RM &SFG) 8% Innovation & Specialised Pro
Slide 76: Production sites
Production sites Hungary China Tatabánya Zhuhai • Ostomy care products • Continence care products • Adhesives • Ostomy care products • Continence care products • Machine building • Interventional Urology products • Number of employees in production: ~1,050 • Number of employees in production: ~1,950
Slide 77: Production sites
Production sites Denmark US Mørdrup Minneapolis • Pilot development work Ostomy care, • Interventional Urology products Continence care and Wound care • Number of employees in production: ~100 • Adhesives production • Number of employees in production: ~100 France Mankato • Skin care products Sarlat
Slide 78: Coloplast establishes Sponsored Level 1 ADR programme in US
Coloplast establishes Sponsored Level 1 ADR programme in US Coloplast Sponsored ADR Programme Benefits of a Coloplast ADR programme to US Investors: • Coloplast has established a sponsored ADR programme in the US, as a Symbol CLPBY service to US investors by offering an alternative way to trade Colo
Slide 79: Contact Investor Relations
Contact Investor Relations Holtedam 1 DK-3050 Humlebæk Denmark Ellen Bjurgert Rasmus Sørensen Hannah Katrine Larsen Vice President, Investor Relations Senior Manager, Investor Relations Investor Relations Coordinator & PA Tel. direct: +45 4911 3376 Tel. direct: +45 4911 1786 Tel. direct: +45 4911 36
Slide 80: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast Group - Ostomy Care /